The article “Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation” examines the use of MSCs in treating steroid-refractory acute and late-acute GvHD. In a study involving 76 patients, MSC therapy showed higher response rates and better survival outcomes in late-acute GvHD compared to acute GvHD, with no infusion-related adverse effects. The results support further research to optimize MSC-based treatments for late-acute GvHD.